Patents by Inventor Franz Ertl
Franz Ertl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180086835Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: November 21, 2017Publication date: March 29, 2018Inventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Patent number: 9850307Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: GrantFiled: September 2, 2015Date of Patent: December 26, 2017Assignee: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20150361176Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: September 2, 2015Publication date: December 17, 2015Inventors: Andrew BEATON, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Patent number: 9150651Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: GrantFiled: January 4, 2012Date of Patent: October 6, 2015Assignee: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20130302335Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.Type: ApplicationFiled: January 4, 2012Publication date: November 14, 2013Applicant: Glaxo Group LimitedInventors: Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
-
Publication number: 20120076787Abstract: The invention relates to combinations of TNF? antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNF? or a TNF? receptor and/or VEGF or a VEGF receptor.Type: ApplicationFiled: May 26, 2010Publication date: March 29, 2012Inventors: Peter Adamson, Peter Franz Ertl, Volker Germaschewski, Gerald Wayne Gough, Michael Steward
-
Patent number: 7655235Abstract: The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.Type: GrantFiled: November 3, 2003Date of Patent: February 2, 2010Assignee: Glaxo Group LimitedInventor: Peter Franz Ertl
-
Publication number: 20090274726Abstract: The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist.Type: ApplicationFiled: September 3, 2007Publication date: November 5, 2009Inventors: Sara Jane Brett, Michael Nail Burden, Peter Franz Ertl, Paul Andrew Hamblin, John Philip Tite
-
Publication number: 20090208515Abstract: The present invention relates to virus vectors comprising oligonucleotides encoding HIV polypeptides, more particularly wherein the virus vector is an adenovirus. In particular, such adenoviruses are non-human primate adenoviruses such as simian adenoviruses, more particularly chimpanzee adenoviruses. In particular the invention relates to adenovirus vectors which comprise HIV polynucleotide sequences which encode multiple different HIV antigens, for example two or three or more HIV antigens. The invention further relates to methods of preparing the virus vectors, to the virus vectors produced by the methods and to the use of the vectors in medicine especially prophylactic or therapeutic vaccination.Type: ApplicationFiled: May 10, 2006Publication date: August 20, 2009Inventors: Peter Franz Ertl, John Philip Tite, Catherine Ann Van Wely
-
Publication number: 20090203144Abstract: The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.Type: ApplicationFiled: January 17, 2008Publication date: August 13, 2009Inventors: ANDREW BEATON, PETER FRANZ ERTL, GERALD WAYNE GOUGH, ANDREW LEAR, JOHN PHILIP TITE, CATHERINE ANN VAN WELY
-
Publication number: 20090130126Abstract: The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated.Type: ApplicationFiled: March 7, 2007Publication date: May 21, 2009Inventors: Ian Richard CATCHPOLE, Jonathan Henry ELLIS, Peter Franz ERTL, John Richard RHODES
-
Patent number: 7132262Abstract: The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections and the symptoms and diseases associated therewith. More particularly, the invention relates to polynucleotide sequences which encode human papilloma virus (HPV) amino acid amino acid sequences, wherein the codon usage pattern of the polynucleotide sequences resemble those of highly expressed mammalian genes.Type: GrantFiled: July 30, 2003Date of Patent: November 7, 2006Assignee: SmithKline Beecham Corp.Inventors: Peter Franz Ertl, Gerald Wayne Gough, Christopher Jeffrey Alan Ring, Vanita Parmar, Sarah Marina Walcott
-
Publication number: 20040082531Abstract: The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated.Type: ApplicationFiled: October 29, 2003Publication date: April 29, 2004Inventors: Ian Richard Catchpole, Jonathan Henry Ellis, Peter Franz Ertl, John Richard Rhodes
-
Patent number: 4485565Abstract: A drying arrangement for strips or sheets of photosensitive material includes a pair of infrared heating rods which are located on opposite sides and extend transversely of the path of travel of the photosensitive material. A parabolic reflector is associated with each of the heating rods and serves to direct radiant energy from the same onto the photosensitive material. The heating rods lie at the focal points of the respective parabolic reflectors. Each of the reflectors has a symmetry plane which is inclined with reference to the path of the photosensitive material in such a manner that the line of intersection of the symmetry plane and the path is situated downstream of the location where a perpendicular from the focal point of the reflector to the path intersects the latter. By virtue of this arrangement, more radiant energy is directed to the upstream portion of the drying arrangement than to the downstream portion thereof. As a result, a thermal gradient exists in the drying arrangement.Type: GrantFiled: June 11, 1982Date of Patent: December 4, 1984Assignee: Afga-Gevaert AktiengesellschaftInventors: Franz Ertl, Adolf Fleck, Nikolaus Jelinek, Rudolph Loistl, Ernst Widemann
-
Patent number: 4370046Abstract: A processing bath is accommodated in a container having a pipe which communicates with the interior of the container at two different locations of the latter. The bath is circulated through this pipe and a pump for circulation of the bath is provided in the pipe. Several tubes extend into the bath and each tube has an outlet opening in the region of the inlet end of the circulation pipe. The outlet openings of the tubes are all located at different levels below the surface of the bath. The tubes are respectively connected with supply pumps which, in turn, are connected with respective sources of concentrates and a diluent required to maintain the strength of the bath within predetermined limits. A sensor senses the amount of material processed in the bath and causes the supply pumps to pump the concentrates and diluent into the bath in dependence upon the amount of material processed.Type: GrantFiled: July 28, 1981Date of Patent: January 25, 1983Assignee: AGFA-Gevaert AktiengesellschaftInventors: Leo Van Bouwel, Erwin Geyken, Franz Ertl, Adolf Fleck
-
Patent number: 4002267Abstract: A method of mixing at least one chemical concentrate with a thinning fluid to form a predetermined amount of a mixture or solution having a predetermined composition, particularly for use in photographic processing operations. Predetermined amounts of the concentrates are placed into respective holding units. The contents of the holding units are emptied into a mixing conduit which leads to a supply tank while at the same time thinning fluid is passed through the mixing conduit. The flow of thinning fluid through the mixing conduit is terminated when the amount of thinning fluid which has been passed through the mixing conduit reaches the amount corresponding to the predetermined amounts of the initial concentrates and to the predetermined amount of final solution or mixture desired.Type: GrantFiled: May 8, 1974Date of Patent: January 11, 1977Assignee: AGFA-Gevaert, A.G.Inventors: Marcel Aelterman, Gustaaf De Loucker, Leo Van Bouwel, Emile Stievenart, Horst Koninger, Helmut Schausberger, Franz Ertl, Horst Rohr, Erwin Geyken
-
Patent number: 3978506Abstract: An apparatus and method for neutralizing waste film-processing fluids discharged from a plurality of work stations containing film-processing fluids utilize a container adapted to receive the waste fluids as well as a predetermined quantity of neutralizing fluid. The quantity of neutralizing fluid admitted into the container is a function of the number and/or size of the film-emulsion carriers to be processed in the work station and/or a function of the fluid content of the container itself. A sensor is provided to detect the fluid contents of the container and cooperates with a control value so as to admit the predetermined quantity of neutralizing fluid into the container. A discharge pump is also provided to discharge the neutralized fluid contents of the container to a discharge area.Type: GrantFiled: December 5, 1974Date of Patent: August 31, 1976Assignee: AGFA-Gevaert, A.G.Inventors: Erwin Geyken, Franz Ertl